Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Social media helps expand groundbreaking findings on malaria as potential cancer treatment

Social media helps expand groundbreaking findings on malaria as potential cancer treatment

Stories Oct 23, 2015 4 minutes

Researchers respond to public’s questions and concerns through reddit's Ask Me Anything.

A revolutionary discovery announced last week by scientists at the University of British Columbia, Vancouver Coastal Health, and the BC Cancer Agency revealed that a protein found in malaria could one day lead to the targeted destruction of cancer cells. The research team, including Vancouver Coastal Health Research Institute scientist Dr. Mads Daugaard, was building on knowledge that the malaria parasite produces a protein that targets a particular kind of sugar molecule in the placenta organ in pregnant women; the same sugar molecule is also found in most cancers. They realized that binding the malarial protein, called VAR2CSA, with cancer-fighting drugs could be a method of delivering the drugs directly to cancer tumours. Using VAR2CSA, the researchers were able to halt the growth of various tumours in mice, and in some cases eliminate the tumours entirely, without harming healthy tissue. 

As expected, announcement of the discovery triggered a flurry of media coverage and questions from the public. Wanting to participate in further knowledge exchange and translation, the team answered questions submitted by reddit users via an AMA (Ask Me Anything) on the popular website. Below, Dr. Daugaard answers some of the most popular questions from the forum: 

Q: When might this discovery turn into a cancer treatment for widespread use?
Daugaard:
If we define 'widespread use' as market registration, we are probably looking at six to eight years (best case scenario). We need to do human safety trials (phase 1) and after that phase 2/3 efficacy trials. But before we get to that, we have to resolve a number of technical issues related to production and compound stability.

Q: Fairly often, the media reports on so-called breakthroughs and possible cancer cures, yet these rarely lead to real, effective treatments for cancer. What makes your team's discovery different?
Daugaard:
In principle, we have to deal with the same challenges in the pre-clinical and clinical development phases as any other experimental cancer drug at this stage. However, the main difference here is that, if we succeed, we would likely be able to target most types of human cancer and not only specific subtypes. So – same risk, but extremely high reward!

Q: What are the similarities between placental tissue and cancer tumor tissue that sparked this research endeavour?
Daugaard:
The placental cells proliferate to grow to a 500g heavy organ in 36 to 40 weeks. In that process, these cells invade the uterine tissue as part of the natural placental implementation process. Also, placenta needs to form new blood vessels in order to supply the growing foetus. High proliferation rates, the ability to invade adjacent tissue, and increased vascularization are features shared with cancer, thus studying ‘oncofetal’ similarities may teach us a thing or two about cancer. In our study we identified a carbohydrate structure in cancer as an oncofetal secondary modification, which we can conveniently access and target with a placenta-binding malaria protein.

Q: Is there any knowledge of the treatment’s side effects at this point?
Daugaard:
Although mice also express this carbohydrate structure in placenta, we have not observed significant side effects in mice treated with the malaria-based drug. Moreover, this type of malaria parasite can only sequester to the placenta in humans and does not bind anywhere else in the human body. Combined, this provides us with a level of comfort that the oncofetal carbohydrate structure is only present in placenta and cancer, and not in normal tissue. As such, we are hopeful that the human safety trials will reveal minimal side effects.

Q: What is the research team’s next goal following these findings?
Daugaard:
The next goal is to make the drug batch for human safety trials. We are working closely together with Kairos Therapeutics and VAR2 Pharmaceuticals to test the drug in multiple cancer models and to resolve technical challenges related to production, stability and quality assurance. This is a costly affair and depending on our funding situation this could take two to four years.

Q: What message of realistic optimism and hope do you have for patients who currently have cancer and are hoping that this discovery will help them?
Daugaard:
This is a hard question. This discovery is not likely to pass through clinical testing and registration earlier than six-to-eight years from now, so patients with advanced disease will most likely not be able to receive the potential benefits. But again, it is hard to predict the future and we may be able to move faster than we anticipate. In the end it depends on how many recourses we are able to put into this program.

Q: Do you think we’ll see a cure for cancer in the next 50 years?
Daugaard:
I think in another 50 years we can see very good treatments for cancer, to a point where people die with it rather than from it. The field is always advancing, we have better preventative measures, diagnostics, and treatment options than just a decade ago. I see no stop to this upward trend. New landmark discoveries in immunotherapy and targeted therapies will likely contribute significantly to disease management and, who knows, might offer a cure to at least some types of cancer. I think we have reasons to be optimistic. 

Researchers

Mads Daugaard

Related Articles

Social media supports for caregivers of people with spinal cord injury

Bringing health education into the social media-savvy 21st century

Ask the experts: Why should I carve out research time for social media?

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Vancouver Prostate Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy